Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study

Neurobiology of Aging

Volumn 29, Issue 6, 2008, Pages 812-818

  Lewczuk, Piotr ^a,b   Kornhuber, Johannes ^a,b   Vanderstichele, Hugo ^c   Vanmechelen, Eugeen ^c   Esselmann, Hermann ^d   Bibl, Mirko ^d   Wolf, Stefanie ^d   Otto, Markus ^d   Reulbach, Udo ^a   Kölsch, Heike ^e   Jessen, Frank ^e   Schröder, Johannes ^f   Schönknecht, Peter ^f   Hampel, Harald ^g   Peters, Oliver ^h   Weimer, Erik ⁱ   Perneczky, Robert ^j   Jahn, Holger ^k   Luckhaus, Christian ^l   Lamla, Ulrich ^m   Supprian, Tillmann ⁿ   Maler, Juan Manuel ^a,b   Wiltfang, Jens ^a,b   more..

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Center for Clinical Neuroproteomics   (Germany)

^c INNOGENETICS   (Belgium)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

^h HUMBOLDT UNIVERSITY   (Germany)

ⁱ CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k UNIVERSITY OF HAMBURG   (Germany)

^l HEINRICH HEINE UNIVERSITY   (Germany)

^m UNIVERSITY OF FREIBURG   (Germany)

ⁿ SAARLAND UNIVERSITY   (Germany)

more..

Author keywords

Alzheimer's disease; Amyloid; Biomarkers; Cerebrospinal fluid; Multiplexing; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; TAU PROTEIN; THREONINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DEMENTIA; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AGED; ALGORITHMS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; COGNITION DISORDERS; COMORBIDITY; DEMENTIA; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 42649128419     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.12.010     Document Type: Article

References (36)

1. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., and Blennow K. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58 (2001) 373-379
2. Blennow K., and Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res. Bull. 61 (2003) 235-242
3. Blennow K., Wallin A., and Hager O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol. Scand. 88 (1993) 221-223
4. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., and Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33 (2000) 95-130
5. Bullock R. New drugs for Alzheimer's disease and other dementias. Br. J. Psychiatry 180 (2002) 135-139
6. Carson R.T., and Vignali D.A. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J. Immunol. Methods 227 (1999) 41-52
7. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr. Res. 12 (1975) 189-198
8. Hampel H., Buerger K., Zinkowski R., Teipel S.J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., Ohno H., Vanmechelen E., Vanderstichele H., McCulloch C., Moller H.J., Davies P., and Blennow K. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 61 (2004) 95-102
9. Härting C., Markowitsch H.J., Neufeld H., Calabrese P., and Deisinger K. Deutsche Adaptation der Revidierten Fassung der Wechsler-Memory Scale (WMS-R) (2000), Verlag Hans Huber, Bern, Göttingen
10. Hindmarch I., Lehfeld H., de Jongh P., and Erzigkeit H. The Bayer Activities of Daily Living Scale (B-ADL). Dement. Geriatr. Cogn. Disord. 9 Suppl. 2 (1998) 20-26
11. Hixson J.E., and Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31 (1990) 545-548
12. International Organization for Standardization, 1994. Accuracy (trueness and precision) of measurement methods and results-Part 2: Basic method for the determination of repeatability and reproducibility of a standard measurement method (ISO 5725-2). International Organization for Standardization, Geneva.
13. Jorm A.F. A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol. Med. 24 (1994) 145-153
14. Knopman D. Pharmacotheraphy for Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 1 (2001) 428-434
15. Lewczuk P., Esselmann H., Bibl M., Beck G., Maler J.M., Otto M., Kornhuber J., and Wiltfang J. Tau Protein Phosphorylated at Threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. J. Mol. Neurosci. 23 (2004) 115-122
16. Lewczuk P., Esselmann H., Otto M., Maler J.M., Henkel A.W., Henkel M.K., Eikenberg O., Antz C., Krause W.R., Reulbach U., Kornhuber J., and Wiltfang J. Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau. Neurobiol. Aging 25 (2004) 273-281
17. Lewczuk P., Kornhuber J., and Wiltfang J. The German competence net dementias: standard operating procedures for the neurochemical dementia diagnostics. J. Neural. Transm. 113 (2006) 1075-1080
18. Li M., Ng T.P., Kua E.H., and Ko S.M. Brief informant screening test for mild cognitive impairment and early Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 21 (2006) 392-402
19. Mayeux R. Evaluation and use of diagnostic tests in Alzheimer's disease. Neurobiol. Aging 19 (1998) 139-143
20. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
21. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43 (1993) 2412-2414
22. Mulder C., Scheltens P., Visser J.J., van Kamp G.J., and Schutgens R.B. Genetic and biochemical markers for Alzheimer's disease: recent developments. Ann. Clin. Biochem. 37 (2000) 593-607
23. Olsson A., Vanderstichele H., Andreasen N., De Meyer G., Wallin A., Holmberg B., Rosengren L., Vanmechelen E., and Blennow K. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51 (2005) 336-345
24. Perneczky R., Wagenpfeil S., Komossa K., Grimmer T., Diehl J., and Kurz A. Mapping scores onto stages: mini-mental state examination and clinical dementia rating. Am. J. Geriatr. Psychiatry 14 (2006) 139-144
25. Petersen P.H., Stockl D., Blaabjerg O., Pedersen B., Birkemose E., Thienpont L., Lassen J.F., and Kjeldsen J. Graphical interpretation of analytical data from comparison of a field method with reference method by use of difference plots. Clin. Chem. 43 (1997) 2039-2046
26. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., and Winblad B. Current concepts in mild cognitive impairment. Arch. Neurol. 58 (2001) 1985-1992
27. Reitan R.M. Trail Making Test (TMT) (1979), Hogrefe Verlag, Bern, Göttingen
28. Shulman K.I., Shedletsky R., and Silver I.L. Challenge of time: clock-drawing and cognitive function in the elderly. Int. J. Ger. Psychiatr. 1 (1986) 135-140
29. Storandt M., Grant E.A., Miller J.P., and Morris J.C. Longitudinal course and neuropathologic outcomes in original vs. revised MCI and in pre-MCI. Neurology 67 (2006) 467-473
30. Thalmann B., Monsch A.U., Bernasconi F., Berres M., Schneitter M., Ermini-Fuenfschilling D., Spiegel R., and Staehelin H.B. Die CERAD Neuropsychologische Testbatterie-Ein gemeinsames minimales Instrumentarium zur Demenzabklärung (1998), Memory Clinic, Geriatrische Universitätsklinik Basel, Basel
31. The Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease", 1998. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol. Aging 19, 109-116.
32. Vanderstichele H., De Meyer G., Andreasen N., Kostanjevecki V., Wallin A., Olsson A., Blennow K., and Vanmechelen E. Amino-truncated β-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin. Chem. 51 (2005) 1650-1660
33. Vignali D.A. Multiplexed particle-based flow cytometric assays. J. Immunol. Methods 243 (2000) 243-255
34. Wiltfang J., Esselmann H., Smirnov A., Bibl M., Cepek L., Steinacker P., Mollenhauer B., Buerger K., Hampel H., Paul S., Neumann M., Maler M., Zerr I., Kornhuber J., Kretzschmar H.A., Poser S., and Otto M. β-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann. Neurol. 54 (2003) 263-267
35. Wiltfang J., Lewczuk P., Riederer P., Grünblatt E., Hock C., Scheltens P., Hampel H., Vanderstichele H., Iqbal K., Galasko D., Lannfelt L., Otto M., Esselmann H., Henkel A.W., Kornhuber J., and Blennow K. Consensus Paper of the WFSBP Task Force on biological markers of dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J. Biol. Psychiatry 6 (2005) 69-84
36. Zetterberg H., Wahlund L.O., and Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci. Lett. 352 (2003) 67-69